Strides Pharma Science Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1d7wexroa9wlz8lizt392otk.pdf

Key Takeaways


The Operating Leverage Story

Badree Komandur: "All we want to say is that consistency and sustainable growth has helped us to create the operating leverage, and the multiplier effect is very clearly seen from our results, a 4.6% increase in revenue growth resulted in almost 3x increase in gross margin growth, almost 5x to 6x increase in the EBITDA growth, and almost 20x increase in the operational PAT."

U.S. Market: Steady March to $400 Million

Badree Komandur: "Yes, it will be very steady. That's all we can say that in the next 2.5 years, we should be able to get there is our hope. But of course, external events are there. We have to watch out, and we want to take step by step. And most important thing is we are focused on the sustainability of that revenue or sustainability of that target."

Other Regulated Markets: The Second Engine

Badree Komandur: "Yes. That is what is our plan. And it will -- again, that's a long-term aspiration. When it will happen, we don't know, but we are working towards it."

Beyond Generics: Nasal Sprays and Control Substances


Growth and Access Markets: Mixed Signals


Balance Sheet and Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
U.S. revenue targetReach $400 million run rateBy FY28
Other regulated markets aspirationMirror U.S. market size (~$100 million run rate)Next 2–3 years
Gross margin rangeSustain 55–59% band through disciplined onboardingOngoing, held for 6 quarters
R&D spend$15–20 million annuallyFY26
Nasal Spray filingsFile a few more productsNext 12 months
Nasal Spray revenue contributionApproval and launch of filed products18–24 months from now
Growth markets step-upSubstantial new dollars from regulatory and GTM effortsBeyond FY27–FY28
CapexMaintain H1 run rate (~INR149 crores per half)H2 FY26
Effective tax rate15–20%Full year FY26
Debt reductionApply free cash to reduce debtOngoing
Finance costsGross finance costs to continue improving; net costs may rise slightly in H2H2 FY26

Key Metrics

MetricQ2 FY26
Revenue growth4.6% YoY
Gross margin57.8%, INR706 cr, up 500 bps YoY
EBITDAINR232 cr, margin 19%, up 320 bps YoY
Operational PATINR140 cr, highest ever quarterly operational PAT
Operational EPSINR15.2, highest ever quarterly EPS
Reported PATINR132 cr
EBITDA to operational PAT conversion57%
Operating costs39% of sales
U.S. revenue$73 million, +2% YoY
Other regulated markets growth16% YoY
Growth markets revenue$17 million, +7% YoY
Rest of world markets revenueINR1,030 cr, crossed INR1,000 cr threshold
Net debtINR1,449 cr, EBITDA to net debt ratio at 1.65x
ROCE16%, improved from 14.9% in March '25
Cash-to-cash cycle113 days, improved 3 days QoQ